Data as of Oct 28, 2026.

vsCompare their flowsaskIQ about these two fundsAsk the committee about these two funds
Across categories

MAGS vs XBI: Differences, Returns & Fees

Share
Share on XDownload as PDF

Over the year to Oct 28, 2026, MAGS returned +5.8% to XBI's +41.2%, and MAGS charges 0.30% to XBI's 0.35%.

askIQ about this page

askIQ about MAGS and XBI

Net assets: $5.5bn on Oct 28, 2026 for Roundhill Magnificent Seven ETF, and $10.3bn on Oct 27, 2026 for State Street SPDR S&P Biotech ETF.

At a glance
+5.8%
MAGS total return, 1 year
+41.2%
XBI total return, 1 year
0.30%
MAGS expense ratio
0.35%
XBI expense ratio

Pair scorecard

MAGS costs 0.05 points a year less; their one-year returns differ by 35.4 points; XBI is 1.9 times larger.

MAGS vs XBI: Differences, Returns & Fees
MeasureMAGSXBI
Return
Total return, 1 year+5.8%+41.2%
Drawdown
Below its high4.1%, high on Oct 13, 2026
Below its all-time high8.9%, high on Feb 8, 2021
Benchmark
What it tracksNo index, actively managedBiotech
Cost and size
Expense ratio0.30%0.35%
Net assets, as of Oct 27, 2026$5.5bn$10.3bn
Active share vs the S&P 50098%
Holdings
Holdings in common0%
Top ten holdings, share of the fund29.3%18%

Holdings in common uses holdings dated Jun 30, 2026 and Oct 27, 2026. Method

What they share

0%

By the books each fund has filed, MAGS and XBI hold 0% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Oct 27, 2026.

0 half 100%

half

0% in common

Positions both hold · largest shared weight first MAGS XBI
Only in one fund ↓
Only in MAGS
Roundhill Ultra Short Duration 6.83%
NVIDIA Corp 3.52%
Apple Inc 3.49%
Amazon.com Inc 3.48%
Tesla Inc 3.45%
Microsoft Corp 3.07%
Meta Platforms Inc 3.04%
Alphabet Inc 2.45%
Only in XBI
MODERNA INC 2.24%
TWIST BIOSCIENCE CORP 1.86%
NATERA INC 1.82%
BIOGEN INC 1.75%
HALOZYME THERAPEUTICS INC 1.75%
UNITED THERAPEUTICS CORP 1.71%
AMGEN INC 1.68%
ABBVIE INC 1.67%
Check overlap with more funds →

Side by side

MAGS Roundhill Magnificent Seven ETF XBI State Street SPDR S&P Biotech ETF
Where it sits Stock ETF Thematic ETF
What it is Actively managed Biotech
Total return, 1 year +5.8% +41.2%
Expense ratio 0.30% 0.35%
Already in the S&P 500 22.5% 13.2%
Holdings 8 165
Net assets, MAGS as of Oct 28, 2026 and XBI as of Oct 27, 2026 $5.5bn $10.3bn

MAGS and XBI on the fields both publish, as of Oct 28, 2026. Source: ETFIQ.

Alert

MAGS and XBI flows, by email on Sundays.

One-click unsubscribe. See Privacy.

About each fund
MAGS

MAGS is actively managed and tracks no index. Over the year to Oct 28, 2026 it returned +5.8% with distributions reinvested. The prospectus expense ratio is 0.30% a year. By its holdings filed for Jun 30, 2026, 22% of the fund by weight is stocks the S&P 500 also holds, across 8 positions, with the top ten at 29.3%. It sat 4.1% below its high of Oct 13, 2026 on Oct 28, 2026.

XBI

By weight, 13% of XBI's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 18% of the fund across 165 positions, as published by its issuer for Oct 27, 2026. Over the year to Oct 28, 2026 the fund returned +41.2% with distributions reinvested. It sits 8.9% below its all-time high of Feb 8, 2021.

Questions people ask

Are MAGS and XBI in the same category?
MAGS is a stock ETF and XBI is a thematic ETF, so they do different jobs. The table compares what both publish: return, cost and holdings.
Which returned more over the last year, MAGS or XBI?
In the year to Oct 28, 2026, with distributions reinvested, MAGS returned +5.8% and XBI +41.2%.
Which is cheaper, MAGS or XBI?
MAGS is cheaper, by 0.05 percentage points a year. That is about $5 on $10,000 held for a year. Fees come from each fund's prospectus.
How much do MAGS and XBI overlap with the S&P 500?
By their latest filed holdings, 22% of MAGS and 13% of XBI by weight is stocks the S&P 500 already holds.
Other comparisons
Cite this pageCitation, APA and Markdown

ETFIQ, MAGS against XBI, data as of Oct 28, 2026. https://etfiq.com/compare/any/mags-vs-xbi

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.